ABSTRACT
No disponible
Subject(s)
Humans , Glucocorticoids/pharmacokinetics , Antiviral Agents/pharmacokinetics , Bell Palsy/drug therapy , Facial Paralysis/drug therapyABSTRACT
UNLABELLED: Intravenous immunoglobulin (IVIG) use in non-approved indications, the increase in consumption and its high cost recommend rationalisation in its utilisation. AIMS: To assess the use of IVIG in Spanish hospitals. METHODS: An observational, prospective and multicentre drug utilisation study was conducted in 13 tertiary Spanish hospitals. Data were collected for 3 months in patients receiving any IVIG. Patient demographics, indication for IVIG use, dosage regimen and cost of treatment were collected. RESULTS: Five hundred and fifty-four patients (mean age of 52 years) were included in the study. A total of 1,287 prescriptions were administered, and the average number of prescriptions per patient was 2.3. The mean daily dose was 24 g (range 0.6-90 g). Overall, IVIG was prescribed for authorised indications in 335 patients (60%) with 953 prescriptions (74%), for non-authorised indications with scientific evidentiary support in 86 patients (16%) with 137 prescriptions (11%), and non-authorised and non-accepted indications in 133 patients (24%) with 197 prescriptions (15%). The most frequent authorised indications were primary and secondary immunodeficiencies, and the most frequent non-authorised and non-accepted indications were multiple sclerosis and bullous dermatosis. The mean cost of IVIG per patient for authorised indications was 2,636.2
Subject(s)
Drug Costs , Drug Utilization/statistics & numerical data , Hospitals, General/statistics & numerical data , Immunoglobulins, Intravenous/economics , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/economics , Immunologic Factors/therapeutic use , Off-Label Use/statistics & numerical data , Adult , Aged , Drug Utilization/standards , Empathy , Female , Humans , Immunoglobulins, Intravenous/administration & dosage , Immunoglobulins, Intravenous/adverse effects , Immunologic Factors/administration & dosage , Immunologic Factors/adverse effects , Male , Middle Aged , Prospective Studies , SpainABSTRACT
No disponible
No disponible
